Related Experiment Video
Updated: Jun 12, 2025
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Prognostic value of systemic inflammation response index in patients with glioma: a meta-analysis
1Department of Medical Oncology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
Background:
The systemic inflammation response index (SIRI) has been investigated for its prognostic relevance in patients with glioma; however, findings remain inconsistent. Therefore, this meta-analysis aimed to clarify the prognostic value of SIRI in glioma.
Methods:
PubMed, Web of Science, Embase, Cochrane Library, and CNKI were systematically searched through December 28, 2024. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to assess the association between SIRI and glioma prognosis.
Results:
A total of 10 studies including 1,942 participants were analyzed. Elevated SIRI was significantly associated with poorer overall survival (OS) (HR=1.67, 95% CI=1.46-1.91, p<0.001) and shorter progression-free survival (PFS) (HR=1.80, 95% CI=1.29-2.52, p=0.001). Subgroup analyses indicated that the prognostic value of SIRI for OS and PFS was consistent regardless of sample size, pathological subtype, cutoff value, or type of survival analysis (p<0.05). Sensitivity and publication bias analyses confirmed the robustness of the results.
Conclusion:
This meta-analysis demonstrates that high SIRI is a significant predictor of OS and PFS in patients with glioma. SIRI may serve as a promising prognostic biomarker in glioma-related clinical practice.
